American Association for Cancer Research

Drug Sensitivity and Resistance: Improving Cancer Therapy

Precision Medicine Series:
Drug Sensitivity and Resistance: Improving Cancer Therapy

June 18-21, 2014
Hyatt Regency Grand Cypress
Orlando, FL
Abstract submission deadline: Wednesday, April 16
Advance registration deadline: Monday, May 12

CONFERENCE CO-CHAIRPERSONS:
Gideon Bollag, Plexxikon, Inc., Berkeley, CA
Elaine R. Mardis, Washington University School of Medicine, St. Louis, MO
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX
David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY

This AACR Precision Medicine Series conference will focus on the critical points at which cancer becomes resistant to treatment. Research presented will address acquired resistance (secondary genetic alterations or changes in signaling pathways), adaptive resistance (DNA/RNA/protein or microenvironment-mediated), preexisting resistance from tumor heterogeneity or clonal selection, and lessons learned from “extreme” responders to therapy. This conference will also focus on new technologies, diagnostics, and noninterventional assessments to detect emerging resistance to treatment. Elucidating resistance mechanisms and exploiting cancer vulnerabilities to therapeutics will ultimately improve cancer therapy and patient care. This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry.

Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available